Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmazz and Dr. Reddy’s to Market Centhaquine as Resuscitative Agent for Shock in India
Details : Under the agreement, Dr. Reddy's has exclusive rights to market and distribute Lyfaquin, an innovative drug developed by Pharmazz, indicated for hypovolemic shock treatment.
Brand Name : Lyfaquin
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 22, 2024
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The positive results seen in the Phase III study indicate that Lyfaquin (centhaquine) is a highly safe and efficacious resuscitative agent as an adjuvant to the standard of care and would be a addition to the U.S. Military’s medical resources that can ...
Brand Name : Lyfaquin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Centhaquine converts the venous unstressed blood volume to stressed blood volume and improves cardiac output and blood circulation. Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.
Brand Name : Lyfaquin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2021
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lyfaquin® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care profe...
Brand Name : Lyfaquin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2021
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).
Brand Name : Lyfaquin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2020
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmazz Receives Marketing Authorization for Lyfaquin™ (centhaquine) from Indian Regulatory Agency
Details : Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2020
Lead Product(s) : Centhaquine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Centhaquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmazz Highlights Positive Impacts of Centhaquine on COVID-19 Patients.
Details : Pharmazz has completed a multi-centric phase 3 study to assess the efficacy of centhaquine as a resuscitative agent to be used as an adjuvant to standard treatment in hypovolemic shock patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2020
Lead Product(s) : Centhaquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?